In this phase 3 , multinational , double-blind , randomised controlled trial , we randomly assigned healthy women older than 25 years to the HPV 16/18 vaccine or control ( 1:1 ) , via an internet-based system with an algorithm process that accounted for region , age stratum , baseline HPV DNA status , HPV 16/18 serostatus , and cytology .